Business context and reporting period
Equillium, Inc. filed its Form 10-K for the fiscal year ended December 31, 2018; it is an annual report, not a standalone quarterly filing. The company is a clinical-stage biotechnology business developing EQ001 (itolizumab), an antibody targeting CD6, for severe autoimmune and inflammatory diseases. It had no product revenue and no product approved for sale in the United States or Canada. The filing was signed March 27, 2019.
Financial performance and liquidity
| Metric | 2018 | Prior period |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $4.94 million | $1.33 million |
| General and administrative expense | $3.67 million | $0.38 million |
| Net loss | $13.25 million | $2.26 million |
| Operating cash used | $7.53 million | $0.66 million |
| Cash, cash equivalents and short-term investments at year-end | $65.91 million | $7.10 million in cash and cash equivalents; no short-term investments |
The prior-period figures are for March 16, 2017 (inception) through December 31, 2017, not a full fiscal year. The company reported a $15.51 million accumulated deficit. Revenue-based margins are not meaningful because the company had no revenue. Year-end total liabilities were $2.23 million, including $2.03 million current liabilities; convertible notes were no longer outstanding after converting into shares at the IPO. The company reported no off-balance-sheet arrangements.
2018 financing provided $66.37 million net cash, principally from the IPO and follow-on share sale. The IPO and partial underwriters’ option generated approximately $64.5 million net proceeds, which the company said had not been used by year-end. Management estimated existing cash and investments would fund planned operations for at least 24 months from year-end, while noting that assumptions could change and additional capital would be needed to complete development and commercialization.
Fourth-quarter detail
Unaudited Q4 2018 operating expenses were $4.23 million and net loss was $4.99 million, versus $0.64 million and $1.11 million, respectively, in Q4 2017. Q4 2018 loss per share was $0.31, compared with $0.10 in Q4 2017. Quarterly results are not necessarily indicative of future results.
Material changes versus the prior period
Operating expenses rose as the company expanded research, clinical development, staffing and public-company operations. R&D expense increased $3.61 million and G&A expense increased $3.29 million from the 2017 inception period. The 2018 net loss also included $2.56 million of interest expense, largely non-cash, and a $2.42 million non-cash charge from remeasurement of Biocon’s anti-dilution right; that right was settled in shares at the IPO. Cash and investments increased substantially following the IPO, while operating cash use also increased.
Outlook, risks and unusual items
- Development plans: The aGVHD Phase 1b/2 trial began in Q1 2019, after the reporting year; top-line Phase 1b data were expected in Q1 2020. Management planned Phase 1b proof-of-concept trials in uncontrolled moderate-to-severe asthma in Q2 2019 and lupus nephritis in the second half of 2019. These are forward-looking plans, not reported outcomes.
- Regulatory designations: EQ001 received FDA Fast Track designation for aGVHD in December 2018 and orphan designations for aGVHD prevention and treatment in February 2019. These designations do not assure approval.
- Safety and clinical uncertainty: A prior healthy-volunteer Phase 1 study reported transient decreases in lymphocyte counts; its IV comparability stage ended early after seven subjects, limiting safety and PK data. The company emphasized that later trials may reveal different safety or efficacy results.
- OFAC/Cuba-related contingency: The antibody sequence was developed by Cuban nationals. Equillium relied on an OFAC general license for EQ001 activities, but OFAC had not confirmed its applicability; the company’s request for guidance or a specific license remained pending. If authorization is unavailable, EQ001 development or commercialization could be impeded.
- Partner and supply dependence: Biocon holds the licensed U.S. and Canadian rights’ underlying technology and is Equillium’s exclusive clinical supplier; Equillium relies on Biocon for manufacturing. The license includes up to $30 million in regulatory milestones, up to $565 million in sales milestones, and tiered royalties, as well as development obligations that could affect licensed rights.
- Funding and execution: The company had one product candidate, no approved products, and expected continued losses and negative operating cash flows. Clinical trial delays, manufacturing issues, competition, regulatory requirements, intellectual-property challenges and the need for future financing could materially affect prospects.
- Other: No legal proceedings were reported. The independent auditor issued an unqualified opinion on the financial statements. Management concluded disclosure controls were effective at December 31, 2018; management’s internal-control assessment and auditor attestation were not included under the newly public company transition relief.
Most important facts for investors to verify
- Current cash runway and spending against the stated plan, including whether later financing is required.
- OFAC’s determination and any license covering EQ001’s development and potential commercialization.
- Enrollment, safety, dose selection and clinical results in the aGVHD, asthma and lupus nephritis programs.
- Biocon’s manufacturing capacity, supply terms, and Equillium’s compliance with license diligence milestones and payment obligations.
- Updated share count, potential equity-plan dilution and the impact of future financing on existing shareholders.